Main navigation About Tolmar Science & Innovation Treatments Responsibility Careers News Contact Announcements Stay current on the latest from Tolmar. Explore our recent press releases, articles and company updates. Tolmar is at the forefront of scientific advances. We remain committed to progress and to sharing our efforts in developing new and innovative products. May 18, 2020 Real-World Data Analysis Published in the Journal of Urology Explores Frequency of Late Luteinizing Hormone-Releasing Hormone Agonist (LHRH) Dosing and Impact on Testosterone Suppression in Patients with Prostate Cancer August 02, 2019 Data on Nadir Testosterone Levels Achieved by ELIGARD® (leuprolide acetate) for injectable suspension published in Reviews in Urology September 07, 2017 Tolmar Pharmaceuticals Champions Prostate Cancer Awareness Month May 14, 2017 Data From Tolmar Pharmaceuticals on ELIGARD Demonstrate Serum Leuprolide Levels Required to Maintain Stable, Long-Term Testosterone Suppression Across All Doses Serum Level of Leuprolide Acetate Required to Maintain Low T Established May 08, 2017 Tolmar, Inventor and Developer of ELIGARD® (leuprolide acetate for injectable suspension), Announces Plans to Expand Manufacturing Facilities in Colorado May 06, 2016 Tolmar Pharmaceuticals Announces That FDA Approval Has Been Received For ELIGARD® (leuprolide acetate for injectable suspension) Storage at Room Temperature For up to 8 Weeks May 18, 2015 Data From Tolmar Pharmaceuticals Demonstrate ELIGARD® (leuprolide acetate for injectable suspension) Consistently Suppresses Serum Testosterone Levels in Patients With Advanced Prostate Cancer May 16, 2014 Tolmar Pharmaceuticals Established to Market ELIGARD® (leuprolide acetate for injectable suspension) For Advanced Prostate Cancer in the U.S. and Puerto Rico Tolmar Pharmacueticals, Inc. Footer menu Contact Drug Distribution Accreditation – Learn More Media Privacy Policy Site Map Terms & Conditions ©2018-2020 Tolmar Pharmaceuticals, Inc. All rights reserved. TOLMAR, ELIGARD, FENSOLVI and ATRIGEL are trademarks of the TOLMAR group. Third party trademarks, product names, and copyrights belong to their respective owners. Back to Top